Molecular evidence of cryptotanshinone for treatment and prevention of human cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 7, 2013, Pages 979-987

  Chen, Wenxing ^a,b   Lu, Yin ^a,b   Chen, Guangying ^c   Huang, Shile ^d,e  

^a College of Pharmacy   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c HAINAN NORMAL UNIVERSITY   (China)

^d Department of Biochemistry and Molecular Biology ^*  (United States)

^e LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cancer; Cell death; Cell proliferation; Cryptotanshinone; MTOR; Tanshinones

Indexed keywords

ANDROGEN RECEPTOR; CRYPTOTANSHINONE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; VASCULOTROPIN RECEPTOR 3;

ANTIANGIOGENIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER PREVENTION; CANCER THERAPY; CARDIOVASCULAR EFFECT; CELL DEATH; CELL MOTILITY; CELL PROLIFERATION; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; NEOPLASM; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VASODILATATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL PROLIFERATION; DRUGS, CHINESE HERBAL; HUMANS; NEOPLASMS; PHENANTHRENES; PHENANTHROLINES; SALVIA MILTIORRHIZA; TOR SERINE-THREONINE KINASES;

EID: 84882770622     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113139990115     Document Type: Article

References (89)

1. Scalbert, A.; Andres-Lacueva, C.; Arita, M.; Kroon, P.; Manach, C.; Urpi-Sarda, M.; Wishart, D. Databases on food phytochemicals and their health-promoting effects. J. Agric. Food Chem., 2011, 59(9), 4331-48.
2. Tan, B. K. H.; Bay, B.; Zhu, Y. Novel compounds from natural products in the new millennium: potential and challenges. World Scientific: Singapore, 2004, p. 183.
3. Zhou, L.; Zuo, Z.; Chow, M. S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol., 2005, 45(12), 1345-59.
4. Ji, X. Y.; Tan, B. K.; Zhu, Y. Z. Salvia miltiorrhiza and ischemic diseases. Acta Pharmacol. Sin., 2000, 21(12), 1089-94.
5. Clebsch, B. The New Book of Salvias: sages for every garden. Timber Press: Portland, 2003, p. 196.
6. Hu, P.; Luo, G. A.; Zhao, Z.; Jiang, Z. H. Quality assessment of radix salviae miltiorrhizae. Chem. Pharm. Bull (Tokyo), 2005, 53(5), 481-6.
7. Zhao, K.; Guo, X. H.; Song, J.; Wang, R. T.; Yang, X. J.; Lin G. B.; Yan, Z. Y. Nationwide survey and analysis of the Salvia production. Lishizhen Med. Materia Medica Res., 2010, 21(9), 2307-10.
8. Cheng, T. O. Cardiovascular effects of Danshen. Int. J. Cardiol., 2007, 121(1), 9-22.
9. Chen, L. N.; Zhu, X. X. Advances in study of the pharmacological effects of danshen on hemorheology. Zhongguo Zhong Yao Za Zhi, 2005, 30(8), 630-3.
10. Park, E. J.; Zhao, Y. Z.; Kim, Y. C.; Sohn, D. H. Preventive effects of a purified extract isolated from Salvia miltiorrhiza enriched with tanshinone I, tanshinone IIA and cryptotanshinone on hepatocyte injury in vitro and in vivo. Food Chem. Toxicol., 2009, 47(11), 2742-8.
11. Chen, W.; Luo, Y.; Liu, L.; Zhou, H.; Xu, B.; Han, X.; Shen, T.; Liu, Z.; Lu, Y.; Huang, S. Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycinmediated cyclin D1 expression and Rb phosphorylation. Cancer Prev. Res. (Phila), 2010, 3(8), 1015-25.
12. Takiura, K. Study on components of Danshen_the structure of cryptotanshinone. J. Pharm. Soc. Japan, 1941, 61(12), 482-90.
13. Takiura, K. Study on components of Danshen_isolation of pigments. J. Pharm. Soc. Japan, 1941, 61(12), 475-82.
14. Yang, Y. B. The determination of stability of cryptotanshinone. Yunnan J. Tradit. Chin. Med. Materia Medica, 1990, 11(3), 24-5.
15. Dong, C.; Qiao, J. L.; Yang, P. Study on the fluorescence properties of cryptotanshinone and tanshinone IIA and their molecular structures in different acidic media. Chin. J. Spectrosc. Lab., 2000, 17(4), 369-72.
16. Inouye, Y.; Kakisawa, H. Total Syntheses of Tanshinone-I, Tanshinone-II and Crytotanshinone. Bull Chem. Soc., 1969, 42(11), 3318-23.
17. Xie, M. Z.; Shen, Z. F. Absorption, distribution, excretion and metabolism of cryptotanshinone. Yao Xue Xue Bao, 1983, 18(2), 90-6.
18. Xue, M.; Cui, Y.; Wang, H. Q.; Luo, Y. J.; Zhang, B.; Zhou, Z. T. Pharmacokinetics of cryptotanshinone and its metabolite in pigs. Yao Xue Xue Bao, 1999, 34(2), 81-4.
19. Xue, M.; Cui, Y.; Wang, H. Q.; Hu, Z. H.; Zhang, B. Reversedphase liquid chromatographic determination of cryptotanshinone and its active metabolite in pig plasma and urine. J. Pharm. Biomed. Anal., 1999, 21(1), 207-13.
20. Zhang, J.; Huang, M.; Guan, S.; Bi, H. C.; Pan, Y.; Duan, W.; Chan, S. Y.; Chen, X.; Hong, Y. H.; Bian, J. S.; Yang, H. Y.; Zhou, S. A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza. J. Pharmacol. Exp. Ther., 2006, 317(3), 1285-94.
21. Pan, Y.; Bi, H. C.; Zhong, G. P.; Chen, X.; Zuo, Z.; Zhao, L. Z.; Gu, L. Q.; Liu, P. Q.; Huang, Z. Y.; Zhou, S. F.; Huang, M. Pharmacokinetic characterization of hydroxylpropyl-betacyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza). Xenobiotica, 2008, 38(4), 382-98.
22. Cui, Y.; Xue, M.; Luo, Y. J.; Hu, Z. Y.; Zhang, B.; Zhou, Z. T.; Shi, Y. B.; Xia, W. J. Pig oral cryptotanshinone excretion data analysis. Chin. J. Vet. Sci. Tech., 1999, 29(12), 30-2.
23. Song, M.; Hang, T. J.; Zhang, Z.; Chen, H. Y. Effects of the coexisting diterpenoid tanshinones on the pharmacokinetics of cryptotanshinone and tanshinone IIA in rat. Eur. J. Pharm. Sci., 2007, 32(4-5), 247-53.
24. Sun, J. H.; Yang, M.; Ma, X. C.; Kang, J.; Han, J.; Guo, D. A. Microbial biotransformation of cryptotanshinone by Cunninghamella elegans and its application for metabolite identification in rat bile. J. Asian Nat. Prod. Res., 2009, 11(6), 482-9.
25. Zhao, Y.; Lu, Y.; Zheng, S. Z.; Wang, A. Y. Research progress on pharmacological activities of cryptotanshinone. China J. Tradit. Chin. Med. Pharmacy, 2010, 25(11), 1839-41.
26. Shin, D. S.; Kim, H. N.; Shin, K. D.; Yoon, Y. J.; Kim, S. J.; Han, D. C.; Kwon, B. M. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res., 2009, 69(1), 193-202.
27. Chen, L.; Zheng, S. Z.; Sun, Z. G.; Wang, A. Y.; Huang, C. H.; Punchard, N. A.; Huang, S. L.; Gao, X.; Lu, Y. Cryptotanshinone has diverse effects on cell cycle events in melanoma cell lines with different metastatic capacity. Cancer Chemother. Pharmacol., 2011, 68(1), 17-27.
28. Gong, Y.; Li, Y.; Lu, Y.; Li, L.; Abdolmaleky, H.; Blackburn, G. L.; Zhou, J. R. Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice. Int. J. Cancer, 2011, 129(5), 1042-52.
29. Katayama, H.; Sen, S. Aurora kinase inhibitors as anticancer molecules. Biochim. Biophys. Acta, 2010, 1799(10-12), 829-39.
30. Chen, W.; Liu, L.; Luo, Y.; Odaka, Y.; Awate, S.; Zhou, H.; Shen, T.; Zheng, S.; Lu, Y.; Huang, S. Cryptotanshinone activates p38/JNK and inhibits Erk1/2 leading to caspase-independent cell death in tumor cells. Cancer Prev. Res. (Phila), 2012, 5(5), 778-87.
31. Epling-Burnette, P. K.; Liu, J. H.; Catlett-Falcone, R.; Turkson, J.; Oshiro, M.; Kothapalli, R.; Li, Y.; Wang, J. M.; Yang-Yen, H. F.; Karras, J.; Jove, R.; Loughran, T. J. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest., 2001, 107(3), 351-62.
32. Aoki, Y.; Feldman, G. M.; Tosato, G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood, 2003, 101(4), 1535-42.
33. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer, 2009, 9(11), 798-809.
34. Masuda, M.; Wakasaki, T.; Suzui, M.; Toh, S.; Joe, A. K.; Weinstein, I. B. Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers? Curr. Cancer Drug Targets, 2010, 10(1), 117-26.
35. Park, I. J.; Kim, M. J.; Park, O. J.; Choe, W.; Kang, I.; Kim, S. S.; Ha, J. Cryptotanshinone induces ER stress-mediated apoptosis in HepG2 and MCF7 cells. Apoptosis, 2012, 17(3), 248-57.
36. Nurnberg, A.; Kitzing, T.; Grosse, R. Nucleating actin for invasion. Nat. Rev. Cancer, 2011, 11(3), 177-87.
37. Chiou, W. F.; Don, M. J. Cryptotanshinone inhibits macrophage migration by impeding F-actin polymerization and filopodia extension. Life Sci., 2007, 81(2), 109-14.
38. Don, M. J.; Liao, J. F.; Lin, L. Y.; Chiou, W. F. Cryptotanshinone inhibits chemotactic migration in macrophages through negative regulation of the PI3K signaling pathway. Br. J. Pharmacol., 2007, 151(5), 638-46.
39. Hur, J. M.; Shim, J. S.; Jung, H. J.; Kwon, H. J. Cryptotanshinone but not tanshinone IIA inhibits angiogenesisin in vitro. Exp. Mol. Med., 2005, 37(2), 133-7.
40. Suh, S. J.; Jin, U. H.; Choi, H. J.; Chang, H. W.; Son, J. K.; Lee, S. H.; Jeon, S. J.; Son, K. H.; Chang, Y. C.; Lee, Y. C.; Kim, C. H. Cryptotanshinone from Salvia miltiorrhiza BUNGE has an inhibitory effect on TNF-alpha-induced matrix metalloproteinase-9 production and HASMC migration via down-regulated NF-kappaB and AP-1. Biochem. Pharmacol., 2006, 72(12), 1680-9.
41. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1995, 1(1), 27-31.
42. Folkman, J. Angiogenesis. Annu. Rev. Med., 2006, 57, 1-18.
43. Braghiroli, M. I.; Sabbaga, J.; Hoff, P. M. Bevacizumab: overview of the literature. Expert Rev. Anticancer Ther., 2012, 12(5), 567-80.
44. Bian, W. P.; Xu, Y.; Wang, J.; Chen, F. The antiangiogenesis effect of cryptotanshinone on chick embryo chorioallantoic membrane. J. Chin. Microcirculation, 2007, 11(1), 23-6.
45. Tammela, T.; Alitalo, K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell, 2010, 140(4), 460-76.
46. Ji, R. C. Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Rev., 2006, 25(4), 677-94.
47. Luo, Y.; Chen, W.; Zhou, H.; Liu, L.; Shen, T.; Alexander, J. S.; Zheng, S.; Lu, Y.; Huang, S. Cryptotanshinone inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3/ERK and small GTPase pathways. Cancer Prev. Res. (Phila), 2011, 4(12), 2083-91.
48. Malinin, N. L.; West, X. Z.; Byzova, T. V. Oxidation as the stress of life. Aging (Albany NY), 2011, 3(9), 906-10.
49. Lawless, M. W.; O'Byrne, K. J.; Gray, S. G. Targeting oxidative stress in cancer. Expert Opin. Ther. Targets, 2010, 14(11), 1225-45.
50. Van Gaal, L. F.; Zhang, A.; Steijaert, M. M.; De Leeuw, I. H. Human obesity: from lipid abnormalities to lipid oxidation. Int. J. Obes. Relat. Metab. Disord., 1995, 19(Suppl 3), S21-S26
51. Bonda, D. J.; Wang, X.; Perry, G.; Nunomura, A.; Tabaton, M.; Zhu, X.; Smith, M. A. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology, 2010, 59(4-5), 290-4.
52. Zhang, H. D.; Huang, Y. L.; He, J. Q. Inhibition of diterpenoid tanshinones from salvia miltiorrhiza bge. on xanthine oxidase activity. Chin. J. Pharmacol. Toxicol., 2007, 21(3), 174-8.
53. Zhang, H. D.; Chen, M.; Ma, L.; Gu, L. Q. The inhibition on pyrogallol autoxidation of diterpenoid tanshinones from salvia miltiorrhiza bge. Pharmacol. Clin. Chin. Materia Medica, 2004, 20(4), 16-9.
54. Zhang, F. Y.; Chen, S. R.; Mei, Z. R.; Liu, P. Q. Protective effect of cryptotanshinone on glutamaic acid induced injury in cortical neurons. Chin. Pharmaceut. J., 2011, 46(16), 1245-8.
55. Xue, M.; Cui, Y.; Wang, H. Q.; Shi, Y. B.; Zhang, B.; Luo, Y. J.; Zhou, Z. T.; Xia, W. J.; Zhao, R. C. Scavenging effect of diterpenoid tanshinones and some natural products on hydroxyl free radicals. Chin. J. Vet. Drug, 1999, 33(2), 15-8.
56. Park, E. J.; Zhao, Y. Z.; Kim, Y. C.; Sohn, D. H. PF2401-SF, standardized fraction of Salvia miltiorrhiza and its constituents, tanshinone I, tanshinone IIA, and cryptotanshinone, protect primary cultured rat hepatocytes from bile acid-induced apoptosis by inhibiting JNK phosphorylation. Food Chem. Toxicol., 2007, 45(10), 1891-8.
57. Jin, Y. C.; Kim, C. W.; Kim, Y. M.; Nizamutdinova, I. T.; Ha, Y. M.; Kim, H. J.; Seo, H. G.; Son, K. H.; Jeon, S. J.; Kang, S. S.; Kim, Y. S.; Kam, S. C.; Lee, J. H.; Chang, K. C. Cryptotanshinone, a lipophilic compound of Salvia miltiorrhiza root, inhibits TNFalpha-induced expression of adhesion molecules in HUVEC and attenuates rat myocardial ischemia/reperfusion injury in vivo. Eur. J. Pharmacol., 2009, 614(1-3), 91-7.
58. Korkina, L. G.; De Luca, C.; Kostyuk, V. A.; Pastore, S. Plant polyphenols and tumors: from mechanisms to therapies, prevention, and protection against toxicity of anti-cancer treatments. Curr. Med. Chem., 2009, 16(30), 3943-65.
59. Choi, Y. J.; Jeong, Y. J.; Lee, Y. J.; Kwon, H. M.; Kang, Y. H. (-) Epigallocatechin gallate and quercetin enhance survival signaling in response to oxidant-induced human endothelial apoptosis. J. Nutr., 2005, 135(4), 707-13.
60. Coyle, C. H.; Philips, B. J.; Morrisroe, S. N.; Chancellor, M. B.; Yoshimura, N. Antioxidant effects of green tea and its polyphenols on bladder cells. Life Sci., 2008, 83(1-2), 12-8.
61. Chan, W. H.; Wu, H. J.; Hsuuw, Y. D. Curcumin inhibits ROS formation and apoptosis in methylglyoxal-treated human hepatoma G2 cells. Ann. N Y Acad. Sci., 2005, 1042, 372-8.
62. Thayyullathil, F.; Chathoth, S.; Hago, A.; Patel, M.; Galadari, S. Rapid reactive oxygen species (ROS) generation induced by curcumin leads to caspase-dependent and-independent apoptosis in L929 cells. Free Radic Biol. Med., 2008, 45(10), 1403-12.
63. Chen, Q.; Wang, Y.; Xu, K.; Lu, G.; Ying, Z.; Wu, L.; Zhan, J.; Fang, R.; Wu, Y.; Zhou, J. Curcumin induces apoptosis in human lung adenocarcinoma A549 cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Oncol. Rep., 2010, 23(2), 397-403.
64. Filomeni, G.; Graziani, I.; Rotilio, G.; Ciriolo, M. R. trans-Resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways. Genes Nutr., 2007, 2(3), 295-305.
65. Shin, S. M.; Cho, I. J.; Kim, S. G. Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3beta inhibition downstream of poly(ADP-ribose) polymerase-LKB1 pathway. Mol. Pharmacol., 2009, 76(4), 884-95.
66. Massard, C.; Fizazi, K. Targeting continued androgen receptor signaling in prostate cancer. Clin. Cancer Res., 2011, 17(12), 3876-83.
67. Johnson, J. J.; Syed, D. N.; Suh, Y.; Heren, C. R.; Saleem, M.; Siddiqui, I. A.; Mukhtar, H. Disruption of androgen and estrogen receptor activity in prostate cancer by a novel dietary diterpene carnosol: implications for chemoprevention. Cancer Prev. Res. (Phila), 2010, 3(9), 1112-23.
68. Wu, C. Y.; Hsieh, C. Y.; Huang, K. E.; Chang, C.; Kang, H. Y. Cryptotanshinone down-regulates androgen receptor signaling by modulating lysine-specific demethylase 1 function. Int. J. Cancer, 2011, Nov 2. doi: 10.1002/ijc.27343.
69. Yang, X.; Zhang, Y.; Wu, X.; Bae, C. S.; Hou, L.; Kuang, H.; Wang, Y.; Stener-Victorin, E. Cryptotanshinone reverses reproductive and metabolic disturbances in prenatally androgenized rats via regulation of ovarian signaling mechanisms and androgen synthesis. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2011, 300(4), R869-75.
70. Xu, D.; Lin, T. H.; Li, S.; Da, J.; Wen, X. Q.; Ding, J.; Chang, C.; Yeh, S. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells. Cancer Lett., 2012, 316(1), 11-22.
71. Li, X. H.; Yang, X. M.; Wu, X. K. Effects of cryptotanshinone in lowering androgens synthesis for the prenatally androgenized male rats. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2008, 28(11), 1001-4.
72. Zhao, L. L.; Zhang, Y. H.; Wang, N. M.; Wu, X. K.; Hou, L. H. Impact of Cryptotanshinone on the reproductivity and metabolism of male mice with Akt2 deletion. Zhonghua Nan Ke Xue, 2011, 17(7), 662-8.
73. Polak, P.; Hall, M. N. mTOR and the control of whole body metabolism. Curr. Opin. Cell Biol., 2009, 21(2), 209-18.
74. Laplante, M.; Sabatini, D. M. mTOR signaling in growth control and disease. Cell, 2012, 149(2), 274-93.
75. Zhou, H.; Huang, S. Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr. Protein Pept. Sci., 2011, 12(1), 30-42.
76. Kim, E. J.; Jung, S. N.; Son, K. H.; Kim, S. R.; Ha, T. Y.; Park, M. G.; Jo, I. G.; Park, J. G.; Choe, W.; Kim, S. S.; Ha, J. Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMPactivated protein kinase. Mol. Pharmacol., 2007, 72(1), 62-72.
77. Zhang, F.; Zheng, W.; Pi, R.; Mei, Z.; Bao, Y.; Gao, J.; Tang, W.; Chen, S.; Liu, P. Cryptotanshinone protects primary rat cortical neurons from glutamate-induced neurotoxicity via the activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. Exp. Brain Res., 2009, 193(1), 109-18.
78. Dat, N. T.; Jin, X.; Lee, J. H.; Lee, D.; Hong, Y. S.; Lee, K.; Kim, Y. H.; Lee, J. J. Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1. J. Nat. Prod., 2007, 70(7), 1093-7.
79. Yokogami, K.; Wakisaka, S.; Avruch, J.; Reeves, S. A. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr. Biol., 2000, 10(1), 47-50.
80. Fang, P.; Hwa, V.; Rosenfeld, R. G. Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway. Exp. Cell Res., 2006, 312(8), 1229-39.
81. Zhou, J.; Wulfkuhle, J.; Zhang, H.; Gu, P.; Yang, Y.; Deng, J.; Margolick, J. B.; Liotta, L. A.; Petricoin, E. R.; Zhang, Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. U S A, 2007, 104(41), 16158-63.
82. Hashemolhosseini, S.; Nagamine, Y.; Morley, S. J.; Desrivieres, S.; Mercep, L.; Ferrari, S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem., 1998, 273(23), 14424-9.
83. Murooka, T. T.; Rahbar, R.; Platanias, L. C.; Fish, E. N. CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1. Blood, 2008, 111(10), 4892-901.
84. Lawrence, D. M.; Singh, R. S.; Franklin, D. P.; Carey, D. J.; Elmore, J. R. Rapamycin suppresses experimental aortic aneurysm growth. J. Vasc. Surg., 2004, 40(2), 334-8.
85. Jundt, F.; Raetzel, N.; Muller, C.; Calkhoven, C. F.; Kley, K.; Mathas, S.; Lietz, A.; Leutz, A.; Dorken, B. A rapamycin derivative (everolimus) controls proliferation through downregulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood, 2005, 106(5), 1801-7.
86. Luo, Y.; Liu, L.; Rogers, D.; Su, W.; Odaka, Y.; Zhou, H.; Chen, W.; Shen, T.; Alexander, J. S.; Huang, S. Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression. Neoplasia, 2012, 14(3), 228-37.
87. Liu, L.; Luo, Y.; Chen, L.; Shen, T.; Xu, B.; Chen, W.; Zhou, H.; Han, X.; Huang, S. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J. Biol. Chem., 2010, 285(49), 38362-73.
88. Gulhati, P.; Bowen, K. A.; Liu, J.; Stevens, P. D.; Rychahou, P. G.; Chen, M.; Lee, E. Y.; Weiss, H. L.; O'Connor, K. L.; Gao, T.; Evers, B. M. MTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res., 2011, 71(9), 3246-56.
89. Holz, M. K.; Ballif, B. A.; Gygi, S. P.; Blenis, J. MTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell, 2005, 123(4), 569-80.